US Stock MarketDetailed Quotes

TEVA Teva Pharmaceutical Industries

Watchlist

16.780
+0.170+1.02%

Close Feb 26 16:00 ET

16.860
+0.080+0.48%

Pre 08:19 ET

19.23BMarket Cap-11.57P/E (TTM)

Teva Pharmaceutical Industries Key Stats

Teva Pharmaceutical Industries Q4 2024 Earnings Date

Currency：USDJan 29, 2025

	Estimate (YoY)	Actual (YoY)	Vs Estimate (% Chg)
Revenue	4.12B	4.23B	+112.34M
Beat Est.	-7.64%	-5.12%	+2.73%
EPS	0.26	-0.19	-0.45
Miss Est.	-35.44%	-146.34%	-171.78%

Analyst Rating

Strong Buy

Feb 26, 2025

Teva Pharmaceutical Industries Earnings Estimates

Revenue

EPS

EBIT

Revenue is based on 5 analyst forecasts. Estimate data is from S&P, and actual data is from Income Statement

Currency: USD

Actual

Estimate

Date	Period	Revenue/Estimate	Earnings Call
--	2025/Q2	-- / 4.309B	--
--	2025/Q1	-- / 3.998B	--
Jan 29, 2025	2024/Q4	4.229B / 4.117B	--
Nov 6, 2024	2024/Q3	4.332B / 4.125B	--
Jul 31, 2024	2024/Q2	4.164B / 4.045B	--

DatePeriodRevenue/EstimateEarnings Call

--2025/Q2-- / 4.309B--

--2025/Q1-- / 3.998B--

Jan 29, 20252024/Q44.229B / 4.117B--

Nov 6, 20242024/Q34.332B / 4.125B--

Jul 31, 20242024/Q24.164B / 4.045B--

Unlock Free Earnings Estimates

Open Account

Teva Pharmaceutical Industries Earnings Reports

10-K: FY2024 Annual Report

Feb 5 16:15 ET

8-K: Teva Delivers Second Consecutive Year of Growth; Announces Strong Financial Results in Fourth Quarter and Full Year 2024, Led by Generics Performance and Innovative Portfolio Growth

Jan 29 07:05 ET

10-Q: Q3 2024 Earnings Report

Nov 6, 2024 16:15 ET

8-K: Teva Announces Strong Financial Results for the Third Quarter of 2024, led by Generics Performance and Innovative Portfolio Growth; Raises 2024 Financial Outlook including on Revenues, Adjusted EBITDA and Non-GAAP EPS

Nov 6, 2024 07:02 ET

Trending Stocks